ClinicalTrials.gov
public full text
Public Domain
The Optimal Sequential Therapy After Long Term Denosumab Treatment
This study intends to investigate whether Alendronate and Zoledronate can prevent bone mineral density loss after long-term treatment with Denosumab.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation#844032
- Mechanisms and management strategies for exacerbated bone loss following denosumab discontinuation.#439024
- Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts#828164
- Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation#846070
- Risedronate in the Prevention of Osteoporosis in Postmenopausal Women#859384
Record · ID 1197520
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive